FEB 27, 2019 06:00 AM PST

Keynote Presentation: Reimagining Drug Discovery and Development Journey Through AI

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Head of Emerging Technologies, LAS, Novartis
    Biography
      Szczepan Baran, VMD, MS is the Head of Emerging Technologies at Novartis Institutes for Biomedical Research. In this position, he leads global strategic initiatives focused on digital efforts to uncover new scientific insights, generate scientific breakthroughs and collect more physiologically and clinically relevant data & endpoints to optimize reproducibility and clinical translation.

      He has held multiple faculty and startup positions and has served on multiple boards. Currently he is serving as Board Member of North America 3Rs Collaborative and is a Chair of the 3Rs Working Group International Consortium for Innovation & Quality in Pharmaceutical Development. Witin the IQ he leads Digital Vivarium Scoping and Animal Studies Modernization Working Groups.

      Dr. Baran is a graduate of the University of Delaware and the University Of Pennsylvania School of Veterinary Medicine. He completed a residency in Laboratory Animal Medicine and a Masters of Science in Comparative Medicine at the University Of Washington School Of Medicine.

    Abstract:

    AI is transforming drug discovery and development (3D) including clinical trials by increasing efficiencies, decreasing the gap between data and our ability to utilize data and most importantly making this journey patient centric. Non-invasive and non-intrusive animal and patient monitoring technologies lead and continue to lead development of novel digital biomarkers. Incorporation of digital endpoints and computational technologies into nonclinical and clinical trials leads to earlier and objective detection of physiological and behavioral changes, including off-target effects that lead to earlier decisions thereby reducing animal and patient burden. Leveraging recent advances in high-throughput technologies and machine learning provides an opportunity for more precise and more efficient target identification process. This talk will discuss these technologies and present their impact through case studies within clinical and nonclinical phases of 3D.


    Show Resources
    You May Also Like
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 14, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 14, 2019 09:00 AM PDT
    DATE: August 14, 2019TIME: 9:00am PT. 12:00pm ET Implementation of Lean Methodology in Biobanking Operations to standardize sample management processes is effective. Each proce...
    OCT 01, 2019 08:00 AM PDT
    C.E. CREDITS
    OCT 01, 2019 08:00 AM PDT
    DATE: October 1, 2019TIME: 8:00am PTIn the webinar, Introduction to Characterization of Biomolecules Using Analytical Ultracentrifugation, we discussed the fundamentals of analytical...
    Loading Comments...
    Show Resources